Merck Sharp & Dohme
Merck Sharp & Dohme is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
A Single Dose Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1403 Formulations in Healthy Male Participants
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available1 trial-level finding · Read insights
- Sixteen healthy male participants were recruited at a single site in Belgium, with eight participants assigned to each panel.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available2 trial-level findings · Read insights
- The study was conducted at 76 centers in 14 countries.
- A global protocol amendment dated 12 June 2018 incorporated a strategic decision to permanently stop enrollment.
These findings describe the trial, not the service provider’s performance or responsibility.
A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8527 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Participants
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
A Single Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1403 in Healthy Male Participants
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Merck Sharp & Dohme?
The 2026-10-09 snapshot links Merck Sharp & Dohme to 5 distinct CTIS trials. Recorded services include Laboratory services, Clinical monitoring, Data management, Electronic data capture, among 14 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Merck Sharp & Dohme?
The most frequently recorded therapeutic areas are Cardiology, Otolaryngology, Solid Tumor Oncology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Merck Sharp & Dohme conducted?
The linked trials record locations in 4 countries, including Belgium, Spain, Portugal, Romania. These are trial locations, not confirmed office locations or countries where Merck Sharp & Dohme delivered services.
What can this page tell me about Merck Sharp & Dohme's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Merck Sharp & Dohme. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Merck Sharp & Dohme LLC